AtaiBeckley (ATAI) H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference summary

Conference overview

• The event featured over 20 companies with a focus on neurology, including depression, epilepsy, Alzheimer's, ALS, and novel CNS drug delivery methods.

• Panels and fireside chats covered a broad range of neurological indications and industry trends.

Company strategy and differentiation

• Emphasis on addressing significant unmet needs in mental health through compounds with prior human clinical evidence.

• Portfolio includes 8 clinical-stage programs targeting diverse indications such as anxiety, depression, substance use disorder, cognitive impairment, and schizophrenia.

• Focus on a 2-hour in-clinic treatment paradigm, inspired by the commercial success of Spravato.

• Strategic investment in Beckley Psytech added BPL-003 and ELE-101, both designed for the 2-hour treatment window.

Pipeline highlights and clinical progress

• VLS-01, a DMT-based oral thin film, is advancing for treatment-resistant depression, with phase 2 initiation planned later this year.

• Collaboration with Beckley Psytech brings BPL-003 (5-MeO-DMT, intranasal) and ELE-101 into the portfolio, both in phase 2 development.

• BPL-003 showed 45% remission in a phase 2A open-label study; phase 2B trial is designed for robust efficacy and logistical advantages over existing treatments.

• COMP360 (psilocybin) is in phase 3 for treatment-resistant depression, with strong prior phase 2b data and a 12% equity stake held.

• RL-007, targeting cognitive impairment in schizophrenia, is in phase 2b with readout expected mid-next year; prior studies showed pro-cognitive effects.